Clinical Research Directory
Browse clinical research sites, groups, and studies.
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
Sponsor: Novartis Pharmaceuticals
Summary
The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.
Official title: Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation: a French Multicentric Prospective Observational Study
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
192
Start Date
2024-06-17
Completion Date
2027-06-30
Last Updated
2026-01-29
Healthy Volunteers
No
Conditions
Interventions
secukinumab
This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
Locations (22)
Novartis Investigative Site
Nice, France, France
Novartis Investigative Site
Antony, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Calais, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
La Rochelle, France
Novartis Investigative Site
Le Mans, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lorient, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Martigues, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Rodez, France
Novartis Investigative Site
Rouen, France
Novartis Investigative Site
Saint-Mandé, France
Novartis Investigative Site
Saint-Pierre, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Vannes, France